Cormorant Asset Management LP decreased its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 31.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,325,000 shares of the company’s stock after selling 600,000 shares during the quarter. Centessa Pharmaceuticals comprises approximately 1.5% of Cormorant Asset Management LP’s portfolio, making the stock its 16th biggest position. Cormorant Asset Management LP owned 0.99% of Centessa Pharmaceuticals worth $33,138,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after buying an additional 979 shares during the period. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals during the fourth quarter valued at $25,000. Wells Fargo & Company MN lifted its position in Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Centessa Pharmaceuticals during the fourth quarter valued at $36,000. Finally, T. Rowe Price Investment Management Inc. lifted its position in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.
Centessa Pharmaceuticals Trading Up 0.3%
Centessa Pharmaceuticals stock opened at $39.87 on Thursday. The business has a 50-day simple moving average of $39.65 and a two-hundred day simple moving average of $31.11. The company has a market cap of $6.17 billion, a P/E ratio of -22.27 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $12.30 and a 52-week high of $40.26. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23.
Insider Buying and Selling
In related news, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.09% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have recently weighed in on CNTA. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $35.00 to $42.00 in a report on Monday, April 20th. Leerink Partners downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their price target for the company from $36.00 to $40.00 in a report on Wednesday, April 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $41.33.
View Our Latest Analysis on CNTA
Centessa Pharmaceuticals Profile
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Featured Articles
- Five stocks we like better than Centessa Pharmaceuticals
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
